Physician profile
Robert E Harvey
NPI 1740267137
$2,253.20
in general payments reported to CMS, 2019-2025
18 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $185 · 2021: $306 · 2022: $632 · 2023: $294 · 2024: $215 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856 · Education: $27.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.00 |
| Education | $27.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $510.06 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $506.79 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $256.83 | 2020-2025 | Cuvitru, Eohilia |
| Genzyme Corporation | $164.22 | 2020-2025 | |
| Optinose US, INC. | $141.54 | 2021-2025 | |
| Ars Pharmaceuticals Operations, INC. | $116.93 | 2025 | Neffy |
| Csl Behring | $97.36 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $93.81 | 2022-2025 | |
| Octapharma USA, INC. | $73.02 | 2021-2022 | |
| Amgen INC. | $61.11 | 2022-2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $42.83 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $41.90 | 2022-2023 | |
| Aerin Medical INC. | $39.43 | 2022 | |
| Grifols USA, LLC | $39.12 | 2022-2024 | Xembify |
| Kaleo, INC. | $26.41 | 2023 | Auvi-Q |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $15.06 | 2022 | |
| Pfizer INC. | $14.65 | 2023 | |
| Merck Sharp & Dohme LLC | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Harvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.